Company

Reverse translational oncology for precision immunotherapy.

MIORG uses patient-derived tumor samples and state-of-the-art multiomic approaches to identify biomarkers, therapeutic targets, and resistance mechanisms that can be converted into practical oncology assets.

Starting from patients

Our discovery model begins with clinically relevant human tumor biology, then moves toward target validation, therapeutic design, diagnostic development, and pharma partnering.

M

Mission

Turn cancer immunotherapy resistance into therapeutic and diagnostic assets.

V

Vision

Build a Finnish reverse translational oncology company with global relevance in precision immunotherapy.

W

Why MIORG exists

Many patients still fail to benefit from immune checkpoint therapy because resistance remains insufficiently actionable.

Reverse translational model

From human tumor biology to partnering-ready assets.

MIORG is built around a patient-centric discovery model: clinically relevant biospecimens, multiomic profiling, systems immunology, and functional validation are integrated to discover mechanisms of therapeutic response and resistance. The goal is not discovery for its own sake, but the creation of actionable programs that can support rational combinations for existing immunotherapies, biomarker-guided prognostic tests, and strategic partnerships.

  • Patient-derived discovery using clinically relevant tumor material and biospecimens
  • Multiomic profiling to identify biomarkers, resistance programs, and therapeutic vulnerabilities
  • Functional validation to prioritize targets with real translational and development potential
  • Therapeutic and diagnostic asset generation designed for preclinical proof-of-concept and partnering
Finnish innovation, global oncology problem. MIORG brings a reverse translational drug-discovery mindset into the Finnish biotech environment, connecting academic science, clinical insight, biomarker development, and preclinical asset creation.
Development philosophy

Start with the patient. Build toward the asset.

MIORG’s approach is designed to make target discovery more biologically grounded, functional validation more clinically relevant, and therapeutic development more partnership-ready.

Explore our science